Chugai says FDA grants priority review for Roche’s Enspryng in MOGAD

Reuters2026/09/10 09:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Chugai reported Roche secured FDA Priority Review for Enspryng (satralizumab) in MOGAD for adult, adolescent patients.
US decision deadline set for Jan. 10, 2027.
EMA validated the EU filing for adult MOGAD; European Commission decision expected in Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Chugai says FDA grants priority review for Roche’s Enspryng in MOGAD

You may also like

Crypto prices